GlaxoSmithKline (GSK), Emergent BioSolutions, and the University of Oxford report a new Phase 1 study at the University of Oxford that will investigate the use of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) as a prime-boost to GSK’s Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). The Phase 1 study has a planned enrollment of 38 volunteers of which six will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost.

Emergent BioSolutions manufactured the supply of MVA EBOZ to be used in this Phase I study, which is being conducted in the UK, with support from the Wellcome Trust and the UK Department for International Development.

Source: Emergent Biosolutions